Repros Reports Findings From the Six Month Study of Androxal(R) in Men With Secondary Hypogonadism
February 10, 2014 09:15 ET
|
Repros Therapeutics Inc.
Greater Than 80% of Men Obtained T in the Normal Range
Evidence of Continued Benefit After Treatment Withdrawal
THE WOODLANDS, Texas, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics...
Repros Meets With FDA to Discuss Data Requirements for Androxal(R) in the Treatment of Secondary Hypogonadism
February 06, 2014 00:22 ET
|
Repros Therapeutics Inc.
NDA submission remains anticipated by year end 2014
No additional long-term safety assessments currently planned before NDA submission and review
THE WOODLANDS, Texas, Feb. 6, 2014 (GLOBE...
Repros Initiates Two Head to Head Studies of Androxal(R) Versus the Leading Topical Testosterone Gel
January 08, 2014 09:15 ET
|
Repros Therapeutics Inc.
Studies designed to compare performance of Androxal to testosterone (T) replacement in restoring and maintaining normal testicular function
Anticipated to expand Androxal label and thereby...
Repros Adds Marketing and Commercialization Expertise to Board of Directors
December 19, 2013 16:17 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Dec. 19, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has added Michael Suesserman to the Company's Board of Directors.
Michael...
Repros to Present Data on the Benefits of Testosterone Restoration With Androxal(R) Compared to T Replacement With Gels at 9th Men's Health World Congress
November 25, 2013 15:00 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today reported it will deliver an invited podium presentation at the 9th Men's Health World...
FDA Schedules Face to Face Meeting With Repros to Discuss Androxal(R) Efficacy
November 25, 2013 06:59 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today reported it has been granted a face to face meeting with the FDA to discuss the pivotal...
Repros Therapeutics Inc.(R) Reports Third Quarter 2013 Financial Results
November 07, 2013 09:15 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Nov. 7, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the third quarter ended September 30, 2013.
Liquidity and...
Repros Receives FDA Guidance for Proellex(R) Low Dose Oral Uterine Fibroid Clinical Program
November 04, 2013 16:05 ET
|
Repros Therapeutics Inc.
Company Instructed to Request Lifting of Full Clinical Hold for Oral Proellex for the Treatment of Uterine Fibroids
Oral Study to be Conducted in Parallel to Vaginal Phase 2b Study
THE...
Repros Receives FDA Guidance For Androxal(R) Clinical Program
October 22, 2013 20:00 ET
|
Repros Therapeutics Inc.
FDA instructs Repros to request meeting to discuss adequacy of studies ZA-301 and ZA-302 as evidence of pivotal efficacy
FDA will now consider label claims versus approved testosterone...
Repros Announces Three Studies Accepted for Presentation at the Annual Meeting of the Sexual Medicine Society of North America
October 07, 2013 10:25 ET
|
Repros Therapeutics Inc.
Presentation Titles Include:
Oral Enclomid (Androxal®) Raises Free and Total Serum Testosterone in Hypogonadal Men: Comparison with a Topical Gel
Oral Enclomid (Androxal®)...